scholarly journals 358 Plantar distribution of hand-foot skin reaction related to use of a multikinase inhibitor and hard orthotic shoes in a pediatric patient

2018 ◽  
Vol 138 (5) ◽  
pp. S61
Author(s):  
A. Kusari ◽  
J. Borok ◽  
A. Han ◽  
A. Valderrama ◽  
S. Friedlander
Keyword(s):  
Skin Reaction ◽  
Pediatric Patient ◽  
Multikinase Inhibitor ◽  
Hand Foot Skin Reaction

scholarly journals Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib

2018 ◽  
Vol 24 (28) ◽  
pp. 3155-3162 ◽  
Author(s):  
Masanori Ochi ◽  
Toshiro Kamoshida ◽  
Atsushi Ohkawara ◽  
Haruka Ohkawara ◽  
Nobushige Kakinoki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skin Reaction ◽  
Multikinase Inhibitor ◽  
Hand Foot Skin Reaction

Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis

2013 ◽  
Vol 31 (4) ◽  
pp. 1078-1086 ◽  
Author(s):  
Viswanath Reddy Belum ◽  
Shenhong Wu ◽  
Mario E. Lacouture
Keyword(s):  
Skin Reaction ◽  
Meta Analysis ◽  
The Novel ◽  
Multikinase Inhibitor ◽  
Hand Foot Skin Reaction

A randomized controlled phase II study of the prophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4008-4008 ◽  
Author(s):  
Zhenggang Ren ◽  
Kangshun Zhu ◽  
Haiyan Kang ◽  
Minqiang Lu ◽  
Zengqiang Qu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Skin Reaction ◽  
Controlled Trial ◽  
Statistical Significance ◽  
Advanced Hepatocellular Carcinoma ◽  
Prophylactic Effect ◽  
Multikinase Inhibitor ◽  
Advanced Hcc ◽  
Randomized Controlled ◽  
Hand Foot Skin Reaction

4008 Background: Sorafenib (SOR) has become the standard treatment for advanced hepatocellular carcinoma (HCC). Hand-foot skin reaction (HFSR) is one of the most common adverse events associated with SOR and its occurrence can impact patient quality of life and lead to dose modification or interruption, both of which may negatively impact clinical outcomes. This randomized controlled trial is the first large prospective study to investigate the prophylactic effect of urea-based creams on HFSR associated with SOR. Methods: Patients with advanced HCC treated with SOR were randomly assigned 1:1 to receive prophylactic urea-based cream (Arm A) or best supportive care (BSC) following development of HFSR (Arm B). SOR was administered 800 mg daily. Urea-based cream was given twice daily for up to 12 weeks starting on Day 1. BSC was at the physician’s discretion and excluded urea-based creams. The primary endpoint was the incidence of all-grade HFSR in the first12 weeks. Results: Eight hundred sixty eight patients were enrolled; 439 patients in Arm A and 432 patients in Arm B. There was no difference of baseline characteristics between two arms. Over the 12 week period of study, the incidence of all-grade HFSR was significantly lower in Arm A compared to Arm B; n=246 (56.0%) patients in Arm A versus n=318 (73.6%) patients in Arm B, p<0.0001. The incidence of grade ≥2 HFSR tended to be lower in Arm A compared to Arm B, but did not reach statistical significance; n=96 (21.9%) patients Arm A versus n=126 (29.2%) patients in Arm B, p=0.1638. The median time to the first HFSR event was 2.5 fold longer in Arm A compared to Arm B; 84 days (95% CI 45-93 days) in Arm A and 34 days (95% CI 29-43 days) in Arm B (p<0.001). Conclusions: This is the first large prospective, randomized control trial examining the prophylactic use of urea-based creams for treatment of HFSR associated with a multikinase inhibitor. Compared to BSC, prophylactic topical use of a urea-based cream appears to be effective in preventing and/or delaying the incidence of HFSR associated with SOR treatment in patients with advanced HCC.

scholarly journals Treatment and prevention of hand-foot skin reaction — dermatological adverse effect of regorafenib (literature review)

2019 ◽  
Vol 3 (28) ◽  
pp. 57-61
Author(s):  
E. A. Shatokhina ◽  
L. S. Kruglova ◽  
P. G. Nosikova
Keyword(s):  
Adverse Event ◽  
Skin Reaction ◽  
Tumor Therapy ◽  
Skin Toxicity ◽  
Common Adverse Event ◽  
Published Data ◽  
Multikinase Inhibitor ◽  
Treatment And Prevention ◽  
Hand Foot Skin Reaction ◽  
Unique Mechanism

Regorafenib is an agent of targeted cancer therapy, that is a multikinase inhibitor of angiogenesis, oncogenesis, microenvironment and tumor immune system. Due to the unique mechanism of action, regorafenib is highly effective in the treatment of various tumors. The most common adverse event associated with regorafenib, leading to a dose reduction or its cancellation, is a manifestation of skin toxicity — hand-foot skin reaction. The review compiles published data based on research and experience in managing this dermatological adverse event. Adequate staff and patient awareness, monitoring, prevention, and treatment are necessary to reduce the incidence, duration, and severity of hand-foot skin reaction associated with regorafenib. Determining the optimal management for patients with this complication becomes an essential component of the complex treatment of patients receiving regorafenib anti-tumor therapy, especially considering the fact that hand-foot skin reaction is a marker of its effectiveness.

Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics

2018 ◽  
Vol 35 (4) ◽  
pp. e206-e209 ◽  
Author(s):  
Ayan Kusari ◽  
Jenna Borok ◽  
Allison M. Han ◽  
Alix Jessika Valderrama ◽  
Sheila Fallon Friedlander
Keyword(s):  
Skin Reaction ◽  
Multikinase Inhibitor ◽  
Hand Foot Skin Reaction

The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis

2011 ◽  
Vol 30 (4) ◽  
pp. 1773-1781 ◽  
Author(s):  
Yevgeniy Balagula ◽  
Shenhong Wu ◽  
Xiao Su ◽  
Darren R. Feldman ◽  
Mario E. Lacouture
Keyword(s):  
Systematic Review ◽  
Skin Reaction ◽  
Meta Analysis ◽  
Review Of Literature ◽  
Multikinase Inhibitor ◽  
Hand Foot Skin Reaction

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

Sign in / Sign up

Export Citation Format

Share Document